Pfizer’s $525 Million Acquisition of ReViral

In UK Goodwin Procter, advised on the matter.

Goodwin Procter advised ReViral with a team including Graham Defries (Picture – Corporate M&A), Tim Worden (IP&IT), Katie Leah (Tax M&A and Deal Advisory).

ReViral announced its acquisition by Pfizer. Pfizer will acquire ReViral for a total consideration of up to $525 million, including up front and development milestones.

ReViral is a privately held clinical-stage biopharmaceutical company focused on discovering, developing, and commercialising novel antiviral therapeutics that target respiratory syncytical virus (“RSV”). RSV is a respiratory pathogen, which can lead to severe and life-threatening lower respiratory tract infections in high-risk populations, including young infants, immunocompromised individuals, and older adults. It is estimated to cause infections in approximately 64 million people, resulting in about 160,000 deaths, globally each year.

Pfizer is an American multinational pharmaceutical and biotechnology company. The acquisition expands Pfizer’s innovative anti-infective pipeline and leverages R&D capabilities, manufacturing and commercialization expertise to potentially address a significant unmet need for the treatment of RSV.

The Goodwin team was led by Graham Defries (Picture) with Kenny Walker-Durrant, Jack Christian and Robert Coleman-Lee (Corporate Life Sciences), Tim Worden and Lucy Sharples (Intellectual Property), Katie Leah, Satvi Vepa and Nathan Langford (Tax) and Sarah Jordan (Competition).

Involved fees earner: Jack Christian – Goodwin Procter; Graham Defries – Goodwin Procter; Sarah Jordan – Goodwin Procter; Katie Leah – Goodwin Procter; Lucy Sharples – Goodwin Procter; Satvi Vepa – Goodwin Procter; Kenny Walker-Durrant – Goodwin Procter; Tim Worden – Goodwin Procter;

Law Firms: Goodwin Procter;

Clients: ReViral;

Author: Giulia Di Palma